An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Trial Details

NCT ID

NCT05952557

Phase

PHASE3

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane
Abemaciclib

Locations (sample)

Dothan, Alabama, United States|31.22323,-85.39049
Phoenix, Arizona, United States|33.44838,-112.07404
Tucson, Arizona, United States|32.22174,-110.92648
Fayetteville, Arkansas, United States|36.06258,-94.15743
Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

Women and Men; ≥18 years at the time of screening (or per national guidelines)
Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the…
Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)…
Patients must be randomised within 12 months of definitive breast surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →